WFDC1A inhibitors pertain to a category of chemical agents specifically designed to interact with and inhibit the activity of a protein encoded by the WFDC1 gene, also known as WAP four-disulfide core domain protein 1. The WFDC1 protein belongs to a family of proteins characterized by the presence of a WAP-type four-disulfide core domain, a structural motif that is stabilized by disulfide bridges and is implicated in various protein-protein interactions. The specific function of WFDC1 is still being elucidated, but it is part of a larger group of molecules that have roles in processes that are fundamental to cellular homeostasis. The inhibitors targeting WFDC1A are typically small molecules or peptides that can bind to the active sites or allosteric sites of the protein, altering its function and thus modulating the biochemical pathways in which WFDC1A is involved.
The development of WFDC1A inhibitors is a complex process that relies on a deep understanding of the protein's structure and function. Researchers utilize a variety of techniques, including X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and computational molecular modeling, to gain insights into the interaction between WFDC1A and potential inhibitors. These compounds are often identified through high-throughput screening of chemical libraries or designed based on the known structure of the WFDC1A protein. Once identified, WFDC1A inhibitors are further optimized to improve their specificity and efficacy in modulating the protein's activity. This fine-tuning involves an iterative process of chemical synthesis and biological testing to evaluate how structural changes to the inhibitor molecules affect their interaction with WFDC1A. As such, the inhibitors are crafted to achieve the desired level of inhibition while minimizing off-target effects that could arise from interactions with other proteins sharing similar structural domains.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
JAK2 inhibitor AG-490 prevents the activation of JAK2, thereby reducing STAT3 phosphorylation which is a potential upregulator of WFDC1A expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor LY294002 impedes the PI3K/Akt signaling pathway, which may be involved in the transcriptional regulation of WFDC1A. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
MEK inhibitor U0126 disrupts the MAPK/ERK pathway. Since ERK can influence gene expression patterns, this may lead to reduced expression of WFDC1A. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
p38 MAPK inhibitor SB203580 hampers the p38 MAPK pathway which could be involved in stress response regulation of WFDC1A expression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
JNK inhibitor SP600125 blocks JNK signaling, potentially decreasing transcription factors that regulate WFDC1A expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor Rapamycin can suppress protein synthesis and cell growth, potentially downregulating proteins including WFDC1A. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
EGFR inhibitor Gefitinib may reduce signaling pathways that lead to the expression of WFDC1A as EGFR is linked to the regulation of various genes. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor Bortezomib can lead to the accumulation of regulatory proteins that may otherwise degrade inhibitors of WFDC1A transcription. | ||||||
WZ 4002 | 1213269-23-8 | sc-364655 sc-364655A | 10 mg 50 mg | $180.00 $744.00 | 1 | |
Selective EGFR inhibitor WZ4002, by targeting EGFR, may decrease downstream signaling pathways that could otherwise enhance WFDC1A expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK inhibitor PD98059 disrupts MEK1/2, which are upstream of ERK, potentially leading to decreased activation of transcription factors that could upregulate WFDC1A. |